SVB Leerink Downgrades Moderna (MRNA) to Underperform

SVB Leerink analyst Mani Foroohar downgraded Moderna (NASDAQ: MRNA) from Market Perform to Underperform with a price target of $93.00 (from $111.00).

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $147.57 yesterday.

You May Also Be Interested In

• Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
• ICICI Securities Downgrades Tech Mahindra Ltd. (TECHM:IN) to Reduce (4)
• FactSet Research Systems (FDS) PT Raised to $253 at Jefferies